等待开盘 05-22 09:30:00 美东时间
-0.180
-0.63%
今日重点评级关注:Canaccord Genuity:维持Sagimet Biosciences"买入"评级,目标价从28美元升至49美元;HC Wainwright & Co.:维持Fate Therapeutics"买入"评级,目标价从5美元升至7美元
05-05 11:40
JP Morgan analyst Michael Mueller maintains Curbline Properties (NYSE:CURB) with a Overweight and raises the price target from $30 to $31.
05-05 05:04
今日重点评级关注:HC Wainwright & Co.:维持Protara Therapeutics"买入"评级,目标价从23美元升至27美元;BTIG:维持Black Diamond Therapeutic"买入"评级,目标价从10美元升至11美元
04-30 19:24
Curbline Properties (NYSE:CURB) released first-quarter financial results and ho...
04-28 20:44
Companies Reporting Before The Bell • LGI Homes (NASDAQ:LGIH) is likely to repo...
04-28 19:11
2026 Guidance The Company has updated its guidance for net income attributable to Curbline for 2026 to be from $0.29 to $0.36 per diluted share and Operating FFO to be from $1.20 to $1.23. The Company does not
04-28 18:46
今日重点评级关注:花旗:维持Pegasystems"买入"评级,目标价从70美元升至71美元;巴克莱:维持曼哈顿联合软件"超配"评级,目标价从236美元升至239美元
04-24 12:10
Morgan Stanley analyst Ronald Kamdem maintains Curbline Properties (NYSE:CURB) with a Overweight and raises the price target from $29 to $30.
04-24 01:48
Curbline Properties announced its annual stockholder meeting Curbline will hold its annual stockholder meeting in a virtual-only format on May 7, 2026. Items for stockholder vote include the election of two Class II directors: Jane E. DeFlorio and Barry A. Sholem. Stockholders will also vote on an a
03-24 18:07
今日重点评级关注:韦德布什:维持TScan Therapeutics"跑赢大市"评级,目标价从4美元升至5美元;HC Wainwright & Co.:维持莱斯康制药"买入"评级,目标价从4美元升至6美元
03-06 11:58